AMCP Nexus 2026 Recap: Discussions on Real-World Evidence, Drug Pricing, and Rare Disease

Written by

Inovalon

Quick Navigation

At ACMP Nexus 2026, our RWD & Insights team heard one key theme across the session rooms, poster hall, and at our booth: what evidence will payers and policymakers ask for next?

The stakes for real-world evidence (RWE) are getting higher, causing life sciences organizations to reassess their data and research strategies. They need more complete patient journeys, linked data, and deeper analytics expertise from study design through execution.

This blog covers:

  • Real-world evidence discussions from the event
  • How drug pricing policy is influencing RWE
  • The growing need for more detailed data in rare disease studies

Real-world evidence takes center stage

Real-world evidence had its own stage at AMCP Nexus 2026, while event sessions explored how patient experience data shapes formulary decisions and how precision medicine coverage looks from a real-world lens.

Payers want to see how a therapy performs in routine care. They need real-world data (RWD) showing trends in utilization and outcomes for their members and their comorbidities, ideally, with social drivers of health (SDOH) data included in the study to understand barriers to care that members may need support with.

At our booth, conversations were focused on data linkage, particularly how securely linking open data from EHRs with closed claims can expand the breadth and depth of a patient population. While the need for open vs closed claims and additional data varies based on each specific study design, the RWD landscape is clearly shifting toward more detailed data. Inovalon and OMNY have partnered to offer Linked Datasets that make it easier for life sciences teams to access the more complete data they need to inform RWE objectives.

Drug pricing policy puts new weight on value evidence

Federal pricing policy was another common theme at the event. One session asked whether Maximum Fair Price has reshaped formulary dynamics, while others covered legislative and regulatory updates, the Commissioner’s National Priority Voucher pilot one year in, and coverage models that look beyond drug cost.

As prices draw more scrutiny, the value conversation shifts toward total cost of care and patient access. Utilization management sits at the center of that shift. And prior authorization and step edits influence whether a patient starts therapy and stays on it, so access becomes something manufacturers can measure.

Rare disease research demands precision at small scale

Rare disease had its own spotlight, with sessions covering neuromuscular diseases, Cushing’s syndrome, and a discussion of how payer evidence expectations differ for rare versus common conditions.

Since rare diseases have small populations – and ones that are hard to follow as patients typically switch payers more frequently – every record counts. Real-world data helps fill the gaps left by small or single-arm trials, but only when researchers can create representative patient populations. That’s why life sciences teams are increasingly asking about rare disease feasibility. They need to know data partners can provide the cohort views they need, even when starting with very small patient populations.

Our research at AMCP Nexus 2026: The cost of outpatient IV antibiotics for cUTI

Our Outcomes and Evidence Solutions team put these themes into practice with a poster on complicated urinary tract infection (cUTI). Done in collaboration with Thomas Lodise of Albany College of Pharmacy and Health Sciences, Inovalon co-authors Gabrielle F. Miller, Kelly Birch, and Kiran Sunkari and colleagues analyzed 327,370 adults treated with an outpatient IV carbapenem or ceftriaxone, using claims data and the Inovalon MORE² Registry®.

The costs added up fast. Mean 30-day all-cause medical costs reached $6,081, driven mostly by hospitalizations ($2,242) and emergency department visits ($1,299). For patients diagnosed in the inpatient setting, cUTI-related costs averaged $12,840. The authors point to a need for effective, less resource-intensive treatment strategies. Read the full abstract in the JMCP October 2026 poster abstract supplement.

Exploring the future of RWE

At AMCP Nexus 2026, most conversations came back to high-quality, linked real-world data that can demonstrate what happens to patients in routine care. Whether to understand rare disease treatments, prepare for policy shifts, or win payer formularies, life sciences teams all rely on representative real-world data, regardless of their main objective.

See how real-world data is powering discovery across healthcare via our Research & Publications and how our seasoned experts can help determine the best dataset for your next study.


Inovalon and design® and Inovalon® are trademarks of Inovalon, Inc.